Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial
Chimeric Therapeutics (ASX:CHM) has reported one leukaemia patient has shown a complete response in its latest drug trial.
Corporate Spotlight
Not Yet Available
Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.
No Corporate Spotlight currently available.